We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 567

FDA inspection finds CGMP violations at Bangalore facility

  • Shook Hardy & Bacon LLP
  • -
  • India, USA
  • -
  • June 26 2014

The U.S. Food and Drug Administration (FDA) has issued a warning letter to the president and CEO of Apotex, Inc., claiming that the agency's

Avalon Ventures closes ninth and largest fund

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 13 2011

Avalon Ventures, located near San Diego, California, has reportedly closed capital commitments of $200 million for its ninth and largest fund, Avalon Ventures IX, LP

EU adds pharmaceuticals to water pollution watch list

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • July 11 2013

The European Commission (EC) has added 12 new substances to the European Union's (EU's) priority list of chemicals known to pose a risk to the safety

Federal court upholds FTC rules on reporting certain pharma patent transfers

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 12 2014

Granting the agency's motion for summary judgment, a federal court in the District of Columbia has upheld the U.S. Federal Trade Commission's (FTC's

Comments sought on guidelines for nanotoxicology research papers

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 20 2012

Nature Nanotechnology editors have initiated an effort to develop guidelines that would apply to researchers submitting papers on the toxicity of various nanomaterials

Emergence of global nanobiotechnology industry explored

  • Shook Hardy & Bacon LLP
  • -
  • Global
  • -
  • January 9 2014

According to business and scientific researchers from Australia, Canada and the United States, some 507 firms throughout the world have both

PROLOR Biotech to raise $75 million for clinical trials on growth hormones

  • Shook Hardy & Bacon LLP
  • -
  • Israel, USA
  • -
  • April 19 2012

In an April 6, 2012, filing with the U.S. Securities and Exchange Commission, Israel-based PROLOR Biotech, Inc. has registered the sale of common stock on the American Stock Exchange in an amount not to exceed $75 million

Moneytree report shows increased life sciences investments in Q1 2011

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 19 2011

According to a PricewaterhouseCoopers report on venture capital investments, although fewer deals occurred in the first quarter of 2011 (Q1 2011) as compared to the last quarter of 2010, investment activity increased 5 percent overall

Supplier sentenced for illegal sales of non-approved drugs

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 26 2014

According to the U.S. Department of Justice, a federal court in Virginia has sentenced a U.S. citizen, who owned and operated several companies in

Pharmacy and hospital interests present comments on proposed compounding bill

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 20 2013

Proposed legislation (S. 959) that would give the U.S. Food and Drug Administration (FDA) the authority to oversee compounding pharmacies that ship